Abstract
BackgroundDespite the modern therapies available for treating glioblastoma multiforme (GBM), it is still a deadly disease. The development of new therapeutic strategies for the management of gliomas is therefore crucial. The present study is designed to analyze the therapeutic potentials of synthetic compound N-(2-hydroxyphenyl)acetamide (NA-2) in the treatment of GBM as a single agent or in combination with Temozolomide (TMZ) on glioblastoma cells.MethodsMTT and TUNEL assays were used to detect the growth inhibitory effect and apoptotic activity of NA-2 alone and in combination with TMZ. Synergy was assessed using combination Index method. The expression of apoptosis related markers Bax, Bcl-2 and caspase-3 were assessed by RT-PCR, whereas, the active caspase-3 protein expression was determined using imunocytochemistry.ResultsBoth NA-2 and TMZ inhibited the growth of U87 in a dose dependent manner. The combine administration of NA-2 (0.33 mM) and temozolomide (0.1 mM) significantly enhanced the cell growth inhibition and apoptosis. Furthermore RT-PCR and imunocytochemistry data revealed that cooperative apoptosis induction was associated with increased ratio of Bax to Bcl-2 and active Caspase-3 expression.ConclusionOur findings support that NA-2 possesses strong apoptotic activity and the combined administration of NA-2 and TMZ may be therapeutically exploited for the management of GBM.Electronic supplementary materialThe online version of this article (doi:10.1186/s12935-014-0133-5) contains supplementary material, which is available to authorized users.
Highlights
Despite the modern therapies available for treating glioblastoma multiforme (GBM), it is still a deadly disease
The cytotoxicity or growth inhibitory activity of N-(2-hydroxyphenyl) acetamide (NA-2) was checked on the pancreatic cancer cells (PSN-1 cell line) using the cell titer blue (CTB) assay
Current findings of our experiments demonstrated that NA-2 upregulated B-cell lymphoma associated X (Bax) and down regulated B-cell lymphoma 2 (Bcl-2) expression at transcriptional level
Summary
Despite the modern therapies available for treating glioblastoma multiforme (GBM), it is still a deadly disease. The present study is designed to analyze the therapeutic potentials of synthetic compound N-(2-hydroxyphenyl)acetamide (NA-2) in the treatment of GBM as a single agent or in combination with Temozolomide (TMZ) on glioblastoma cells. Glioblastoma multiforme (GBM) is a malignant, invasive and most commonly occurring tumor of the central nervous system [1,2]. It accounts for approximately 60% of all malignant primary brain tumors in adults [2]. There is a need of developing new compounds which can be use as a single agent therapy or else can be used in combination with low doses of conventional drugs
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
